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Abstract
Background:  Tumor necrosis and apoptotic activity are considered important in cancer
progression, but these features have not been much studied in melanomas. Our hypothesis was
that rapid growth in cutaneous melanomas of the vertical growth phase might lead to tissue
hypoxia, alterations in apoptotic activity and tumor necrosis. We proposed that these tumor
characteristics might be associated with changes in expression of cell adhesion proteins leading to
increased invasive capacity and reduced patient survival.
Methods: A well characterized series of nodular melanoma (originally 202 cases) and other benign
and malignant melanocytic tumors (109 cases) were examined for the presence of necrosis,
apoptotic activity (TUNEL assay), immunohistochemical expression of hypoxia markers (HIF-1 α,
CAIX, TNF-α, Apaf-1) and cell adhesion proteins (αvβ3 integrin, CD44/HCAM and osteopontin).
We hypothesized that tumor hypoxia and necrosis might be associated with increased invasiveness
in melanoma through alterations of tumor cell adhesion proteins.
Results: Necrosis was present in 29% of nodular melanomas and was associated with increased
tumor thickness, tumor ulceration, vascular invasion, higher tumor proliferation and apoptotic
index, increased expression of αvβ3 integrin and poor patient outcome by multivariate analysis.
Tumor cell apoptosis did also correlate with reduced patient survival. Expression of TNF-α and
Apaf-1 was significantly associated with tumor thickness, and osteopontin expression correlated
with increased tumor cell proliferation (Ki-67).
Conclusion:  Tumor necrosis and apoptotic activity are important features of melanoma
progression and prognosis, at least partly through alterations in cell adhesion molecules such as
increased αvβ3 integrin expression, revealing potentially important targets for new therapeutic
approaches to be further explored.
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Background
Multiple features are important for the progress of cutane-
ous melanoma, like alterations of tumor cell proliferation
and cell cycle regulation, cell adhesion proteins, and
tumor associated angiogenesis [1-3]. Although necrosis
and tumor cell apoptosis are strongly related to the behav-
iour of malignant tumors, these characteristics have not
been well studied in human melanomas. We therefore
examined whether these features are associated with the
development and clinical progression of melanocytic
tumors. Selected markers related to tissue hypoxia were
examined, e.g. HIF-1α, CAIX, TNF- α, and Apaf-1. We also
asked whether necrosis was associated with alterations of
tumor phenotype, and the expression of cell adhesion
markers (αvβ3 integrin, CD44/HCAM, osteopontin) was
determined.
Whereas HIF-1α expression has been associated with
decreased survival in cancers of the breast and other sites
[4-7], little is known about its role in melanoma. Expres-
sion of CAIX, another marker of tissue hypoxia [8], has
been associated with tumor progression in some cancers
[9,10], but melanomas were negative in one small study
[11]. TNF-α is an important mediator of apoptosis via the
"extrinsic pathway" [12], but there are limited data on its
role in human melanoma. Apaf-1 is involved in the mito-
chondrial apoptotic pathway, and studies have reported
reduced expression in advanced melanoma and a possible
relationship with melanoma chemoresistance [13-15].
Adhesion molecules are involved in the regulation of cel-
lular migration and tumor invasion [16]. We here asked
whether necrosis and tissue hypoxia are associated with
alterations in cell adhesion markers. Among these, the
integrin receptors are important for the binding of cells to
extracellular matrix components. Experimentally induced
HIF leads to upregulation of αvβ3 integrin followed by
increased invasive capacity [17], supporting our hypothe-
sis. In melanomas, the αv-integrin subunit is widely
expressed, whereas β3  is mainly restricted to vertical
growth phase tumors [16] and associated with poor prog-
nosis [18,19]. CD44/HCAM is also a cell adhesion protein
interacting with matrix components [20], and expression
in melanoma cells has been linked to poor prognosis in
some [21,22] but not all studies [23-25]. The secreted
phosphoprotein osteopontin, which binds to both αvβ3
integrin and CD44 receptors, might influence tumor cell
attachment and migration [26]. In mice, osteopontin defi-
ciency suppresses growth of melanoma cells implanted in
the bone marrow [27]. In metastatic melanoma, Zhou et
al. found by cDNA microarray analysis that osteopontin
was the most overexpressed gene when compared with
benign nevi [28]. Recently, osteopontin expression was
shown to be a marker of lymph node metastases and poor
patient prognosis in melanoma [29].
In our present study, we found that both hypoxia and cell
adhesion markers showed an increased expression from
benign nevi to melanomas, indicating an importance of
these pathways in early melanoma development. In estab-
lished melanoma, tumor necrosis was related to increased
expression of αv-integrin, and both were strongly associ-
ated with features of aggressive tumors and poor patient
outcome as shown by multivariate survival analysis.
Methods
Patient samples
This population-based series has been described in detail
elsewhere [1]. Briefly, 202 cutaneous melanomas of the
nodular type occurring during 1981–97 were initially
included. For the present study, 133 cases had sufficient
material left in the tissue microarray blocks to be studied.
The presence of a vertical growth phase and the lack of a
radial growth phase, i.e. adjacent in situ or microinvasive
component, were used as inclusion criteria for this series.
In addition, 58 paired metastases (local, regional lymph
nodes, distant) were examined. Clinico-pathologic char-
acteristics and some survival data have previously been
reported [1]. For comparison, 31 cases of consecutive
benign melanocytic nevi and 20 cases of superficial
spreading melanomas (median thickness, 1.7 mm) were
included to examine these markers in different stages of
melanocytic tumor progression. The Norwegian Data
Inspectorate and the Regional Committee for Ethics in
Research (Health Region III) have approved this study.
For the present study, HE-slides were re-examined and the
presence of necrotic areas was recorded (see later). Cases
with sufficient material left in the TMA blocks (range 129–
133; differences due to drop-outs) were examined for the
expression of hypoxia related markers (HIF-1α, CAIX,
TNF-α and Apaf-1) and selected cell adhesion markers
(αv-integrin,  β3-integrin, CD44/HCAM, osteopontin).
Apoptotic activity was estimated by the TUNEL assay.
Clinico-pathologic variables
The following variables were recorded: date of histologic
diagnosis, sex, age at diagnosis, anatomical site of the pri-
mary tumor, and presence of metastases at diagnosis. The
following histological features were also included: tumor
thickness according to Breslow [30], level of invasion
according to Clark [31], microscopic ulceration and vas-
cular invasion [32].
Tumor necrosis
The original HE-slides were re-examined (I.M.B., L.A.A.)
and presence of tumor necrosis was evaluated. Necrosis
was recorded as present when an area of at least 1/4 high
power field (0.07 mm2) was occupied by necrotic cells
and sparse when clusters of at least five necrotic cells (but
less than 1/4 HPF) were observed. Cases presenting scat-BMC Cancer 2008, 8:362 http://www.biomedcentral.com/1471-2407/8/362
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tered necrotic cells of less than five in a cluster were
regarded as negative.
Tissue Microarray (TMA)
The technique of TMA is well established [33] and vali-
dated [1,34,35]. For TMA construction [33,35], represent-
ative tumor areas were identified on HE-stained slides,
generally located at the suprabasal areas of the primary
tumors [34]. Three parallel tissue cylinders (diameter 0.6
mm) were sampled from each case. Sections of the result-
ing TMA blocks (5 μm) were then made by standard tech-
nique.
Apoptotic index (TUNEL assay)
Fluorescent terminal deoxyuridine triphosphate (dUTP)
nick-end labeling (TUNEL) staining was performed on the
TMA sections using the In situ Cell Death Detection Kit
(Roche Diagnostic GmbH, Mannheim, Germany) accord-
ing to the manufacturer's instructions. Briefly, the sections
were deparaffinized in xylene and rehydrated in ethanol
before enzymatic retrieval with Proteinase K (Dako Cyto-
mation, Copenhagen, Denmark), followed by blocking
with 4% bovine serum albumin and incubation with a
mixture of TdT solution (enzyme solution) and labelled
dUTP solution (label solution) in 37°C for 1 hour in a
dark humified chamber. After incubation in alkaline
phosphatase converter, fast blue was used as substrate and
hematoxylin eosin as counterstain. The number of
TUNEL-positive tumor cell nuclei was counted in 200
cells by light microscopy and use of an ocular grid, and an
apoptotic index (AI) was determined as the percentage of
tumor cells being positive. In subsequent statistical analy-
ses, AI was divided by the upper quartile (cut-off: AI ≤ 3.5
% versus > 3.5 %). A subset of the cases were blindly
scored by two of the authors, showing good correlation
(Pearson's correlation coefficient 0.91, p < 0.0001).
Immunohistochemistry
The immunohistochemical staining was performed on
thin sections (5 μm) of paraffin-embedded archival tissue,
using TMA sections as described. Samples were dewaxed
and rehydrated with xylene/ethanol before microwave
antigen retrieval and antibody incubation, using proto-
cols optimized for each antibody (Table 1). The staining
procedures, except the protocol for HIF-1α, were all per-
formed using the EnVision labelled polymer method,
with commercial available kits (DakoCytomation,
Copenhagen, Denmark).
Information on Ki-67, p16, p53 [1], tumor associated
angiogenesis estimated by microvessel density (MVD)
[36], E-cadherin, N-cadherin, P-cadherin, and β-catenin
[2] from our previous studies was included for compari-
son.
Evaluation of staining
The staining of HIF-1α was restricted to the nuclei of
tumor cells, as described by others [37]. The staining for
CAIX, TNF-α and Apaf-1 was mainly cytoplasmic and
homogenously distributed. CD44 showed a membranous
staining pattern. The staining of αv and β3 integrin (Fig. 1),
as well as the osteopontin protein, was most pronounced
in the membrane and cytoplasm of the tumor cells.
The immunohistochemical staining was recorded using a
semi-quantitative and subjective grading, considering
both the intensity of staining and the proportion of tumor
cells showing unequivocal positive reaction. Staining
intensity: 0, no staining; 1, weak staining; 2, moderate
staining; and 3, strong staining. Staining area: 0, no stain-
ing; 1, positive staining in < 10% of tumor cells; 2, posi-
tive staining in 10–50% of tumor cells; 3, positive staining
in > 50% of tumor cells. A staining index (SI) was then cal-
Table 1: Immunohistochemical staining methods
Antibody Provider Epitope retrieval Dilution Incubation Signal amplification
HIF-1α, MS-1164, clone 67 
(MoAb)
Neomarkers 15 min in TrisEDTA buffer 
(pH = 9) at 350 W
1:100 60 min RTa CSA (DAKO)
CAIX, NB 100–417 (pAb) Novus Biologicals 15 min in citrate buffer (pH = 
6) at 350 W
1:100 60 min RT no
TNF-α, ab 6671 (pAb) Abcam 15 min in TrisEDTA buffer 
(pH = 9) at 350 W
1:200 Overnight 4°C no
Apaf-1, RB 9236 (pAb) Neomarkers 15 min in citrate buffer (pH = 
6) at 350 W
1:100 60 min RT no
CD51/αv-integrin, MS 1774, 
clone CJ00 (MoAb)
Neomarkers 15 min in EDTA buffer (pH = 
8) at 350 W
1:20 60 min RT no
CD61/β3-integrin, MS 1842, 
clone Y2/51 (MoAb)
Neomarkers 15 min in citrate buffer (pH = 
6) at 350 W
1:25 Overnight 4°C no
CD44/HCAM, MS 668, clone 
156-3C11 (MoAb)
Neomarkers 15 min in citrate buffer (pH = 
6) at 350 W
1:200 60 min RT no
Osteopontin (MoAb) Gift from prof. Ann F. 
Chambers
15 min in citrate buffer (pH = 
6) at 350 W
1:500 60 min RT No
aRT = room temperaturBMC Cancer 2008, 8:362 http://www.biomedcentral.com/1471-2407/8/362
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culated as previously reported, as staining intensity times
positive area [38]. In subsequent statistical analyses, cut-
off points for SI categories were mainly based on median
or quartile values, considering also the frequency distribu-
tion curve and size of subgroups for each marker, as well
as number of cases and events (follow-up information)
when determining the final cut-off points between low
and high expression (two categories). In survival analysis,
subgroups (based on quartiles) with similar survival were
subsequently merged. HIF-1α was categorized as negative
(SI 0–1) and positive (SI ≥ 2), whereas expression of CAIX,
Apaf-1, αv-integrin, and osteopontin was considered low
(SI ≤ 4) and high (SI > 4). TNF-α and β3-integrin were
divided by SI < 3 (low) and ≥ 3 (high), and CD44 was
divided by ≤ 6 (low) and > 6 (high).
Follow-up
Complete information on patient survival and time and
cause of death was available in all 202 cases [2]. Last date
of follow-up was December 31, 1999, and median follow-
up time for survivors was 89 months (range 24–221).
Clinical follow-up (with respect to recurrences) was not
carried out in 14 patients (predominantly older age), and
21 patients were not treated with complete local excision.
Thus, recurrence-free survival was available in 167
patients. During the follow-up period, 72 patients (36%)
Immunohistochemical staining showing (A) strong and (B) weak expression of αv-integrin, and (C) strong and (D) weak  expression of β3 integrin in primary nodular melanoma Figure 1
Immunohistochemical staining showing (A) strong and (B) weak expression of αv-integrin, and (C) strong and 
(D) weak expression of β3 integrin in primary nodular melanoma.BMC Cancer 2008, 8:362 http://www.biomedcentral.com/1471-2407/8/362
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died of malignant melanoma, and 45 (22%) died of other
causes. Of the 167 radically treated patients with data on
recurrence-free survival, 74 (44%) had recurrent disease.
Statistics
Analyses were performed using the SPSS statistical pack-
age, version 12.0 (SPSS Inc, Chicago, IL). Associations
between different categorical variables were assessed by
Pearson's chi-square test. Continuous variables not fol-
lowing the normal distribution were compared between
two groups using the Mann-Whitney U test. The Wilcoxon
signed rank test was used to compare related samples.
Univariate analyses of time to death due to malignant
melanoma or time to recurrence (recurrence-free survival)
were performed using the product-limit procedure (Kap-
lan-Meier method), and differences between categories
were estimated by the log-rank test, with date of histolog-
ical diagnosis as the starting point. Patients who died of
other causes were censored at the date of death. The influ-
ence of co-variates on patient survival was analysed by the
proportional hazards method, and tested by the likeli-
hood ratio (lratio) test. The level for inclusion in Cox'
multivariate regression analyses was P = 0.10, and the co-
variates included (step one) were tumor thickness accord-
ing to Breslow, Clark's level of invasion, tumor ulceration,
vascular invasion, p16 expression and tumor cell prolifer-
ation assessed by Ki-67, in addition to tumor necrosis and
markers of cell adhesion and hypoxia described here.
Results
Tumor necrosis
Necrosis was not present in benign nevi. In nodular
melanomas, tumor necrosis (sparse or significant) was
observed in 57 (29%) of the cases and was associated with
increased tumor thickness (median thickness 5.2 mm
when necrosis was present, as compared to 3.0 mm in
cases without necrosis; p < 0.0001), and with increased
tumor cell proliferation by Ki-67 (35% versus 25% posi-
tive nuclei; p = 0.007). Necrosis was also associated with
tumor ulceration (p < 0.0001) and vascular invasion (p =
0.003), with 68 % of necrotic tumors being ulcerated
compared to 32% of tumors without necrosis. For vessel
invasion, the corresponding figures were 33% versus 15%.
Tumors with necrotic areas had a slightly higher angio-
genesis as estimated by microvessel density, 22.0 micro-
vessels per mm2  (median) in tumors with necrosis,
compared with 19.0 among the rest (p = 0.031). Also,
tumors with necrosis were associated with alterations of
cell adhesion molecules, as shown by increased expres-
sion of cytoplasmic P-cadherin and weaker nuclear β-cat-
enin staining (p = 0.017 and p = 0.002, respectively), both
being associated with aggressive melanomas in our previ-
ous study [2].
Apoptotic index
Benign melanocytic nevi only rarely contained apoptotic
cells (median apoptotic index, AI = 0). When comparing
nevi with melanomas (superficial and nodular melano-
mas combined), there was markedly higher AI among the
latter (p = 0.004) (Table 2), whereas there was no differ-
ence in AI when comparing primary nodular melanomas
with their corresponding metastases. Median AI in nodu-
lar melanomas was 1.5 %. Tumors with necrosis had a
higher apoptotic index (median 2.5) than tumors without
necrosis (median 1.25; p = 0.040). Increased AI was also
associated with tumor ulceration (p = 0.038), and locali-
zation on the trunk (p = 0.040). Loss of p16 protein
expression was associated with high AI (p = 0.008). Fur-
ther, high AI (> 3.5 %, upper quartile) was significantly
associated with reduced angiogenesis by MVD (p = 0.05),
and with alterations of cell adhesion markers, such as
strong expression of the cell adhesion marker β3-integrin
(p = 0.027).
The relative impact of tumor cell proliferation versus
apoptotic activity was estimated by the ratio of Ki-67 and
AI (Proliferation ratio = Ki-67/AI). High proliferation
ratio (above 7.4, cut-point lower quartile) was associated
with increased tumor thickness (p = 0.011).
Cell adhesion related markers
Expression of the αv and β3 integrin subunits and of oste-
opontin was stronger in melanomas than in benign nevi
(p = 0.034, p = 0.001 and p < 0.0001, respectively),
whereas the expression of CD44 was weaker in melano-
mas than in nevi (p = 0.038) (Table 2). In contrast, β3
integrin expression was significantly decreased in
Table 2: Expression of cell adhesion proteins in benign 
melanocytic nevi and cutaneous melanoma
Cell adhesion markers No. of cases pa
Nevi NMb + SSMc
αv-integrin
weakd 15 42
strong 16 104 0.034
β3-integrin
weakd 21 53
strong 10 97 0.001
CD44
weakd 86 9
strong 22 77 0.038
osteopontin
weakd 26 60
strong 5 88 < 0.0001
aChi-square test
bNodular melanoma
cSuperficial spreading melanoma
dCut-point median (SI)BMC Cancer 2008, 8:362 http://www.biomedcentral.com/1471-2407/8/362
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melanoma metastases in reference to the corresponding
primary nodular melanoma tumors (p < 0.0001). Among
nodular melanomas, the αv and β3 integrin subunits were
significantly co-expressed (p = 0.003). Strong αv expres-
sion was associated with presence of tumor necrosis, (p =
0.010), increasing tumor thickness (p = 0.002), and high
levels of cytoplasmic P-cadherin expression (p = 0.009).
Strong expression of β3 integrin was associated with tumor
necrosis (p = 0.001), increased tumor thickness (p <
0.0001), tumor ulceration (p = 0.003), vascular invasion
(p = 0.005), and tumor cell proliferation by Ki-67 expres-
sion (p = 0.019).
CD44 was significantly co-expressed with αv-integrin (p =
0.011) in nodular melanomas. Osteopontin expression
was associated with β3-integrin staining (p = 0.028),
increased tumor cell proliferation by Ki-67 (p = 0.023),
and was significantly increased in metastatic lesions com-
pared with their corresponding primary nodular melano-
mas (p < 0.0001).
Hypoxia related markers
Expression of selected hypoxia markers HIF-1α (p =
0.002), CAIX (p < 0.0001), TNF-α (p = 0.008) and Apaf-1
(p = 0.002) was significantly stronger in melanomas than
in benign nevi (Table 2). Among primary nodular
melanomas, increased tumor thickness was associated
with stronger expression of hypoxia markers TNF-α (p =
0.028) and Apaf-1 (p = 0.05) (Table 3), whereas tumor
ulceration was associated with stronger expression of
hypoxia markers HIF-1α (p = 0.05) and CAIX (p = 0.03).
Expression of Apaf-1, a marker of the mitochondrial
apoptotic pathway, was strongly associated with increased
expression of adhesion markers αv-integrin (p = 0.001)
and CD44 (p = 0.006). Also, Apaf-1 was stronger in met-
astatic lesions when compared with primary nodular
melanomas (p = 0.002).
Survival analyses
Presence of necrosis was associated with significantly
reduced overall survival (Table 3); (Fig. 2), as well as
reduced recurrence-free survival (p = 0.016). High apop-
totic activity (AI) was also significantly associated with
reduced patient survival in univariate analysis (Table 3;
Fig. 2), but not with reduced recurrence free survival (not
shown).
Among the cell adhesion markers, high levels of αv-
integrin expression was associated with significantly
reduced survival (p = 0.006) (Table 3; Fig. 2). The same
trend, although non-significant, was seen regarding
expression of the β3 subunit (p = 0.13).
Among the hypoxia related markers, increased expression
of HIF-1α (p = 0.061), TNF-α (0.059) and Apaf-1 (0.095)
tended to be associated with reduced survival, although of
borderline significance. Strong expression of HIF-1α was
significantly associated with reduced recurrence-free sur-
vival, with 61% of the patients experiencing relapse
within 5 years when HIF-1α was strong versus 50% of
patients when HIF-1α was weak (p = 0.024).
In multivariate analysis, tumor necrosis turned out to be a
strong and independent prognostic factor (HR 2.3, p =
0.001) when included along with basic prognostic factors
like tumor thickness (using median as cut-off value, i.e ≤
vs > 3.55 mm), Clark's level of invasion, tumor ulceration,
vascular invasion, p16 expression and tumor cell prolifer-
ation by Ki-67. When including these variables and necro-
sis along with markers of cell adhesion and hypoxia (all
with p ≤ 0.10 in univariate analysis), both necrosis and αv-
integrin expression remained as independent variables
(final model shown in Table 4).
Table 3: Estimated 5- and 10-year survival rates for patients with vertical growth phase melanoma (product-limit method) by tumor 
necrosis, apoptotic index and αv-integrin, using death from melanoma as end-point
Variables No. of cases Estimated survival rates (%) pa
5 years 10 years
Tumor necrosis
absent 142 76 64 < 0.0001
present 57 45 35
Apoptotic index
lowb 97 66 61 0.016
high 30 49 16
αv-integrin
weakc 39 80 80 0.006
strong 91 56 42
aLog-rank test
bCut-point upper quartile (SI)
cCut-point median (SI)BMC Cancer 2008, 8:362 http://www.biomedcentral.com/1471-2407/8/362
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In this series of nodular melanomas, Clark's level of inva-
sion has a somewhat stronger impact on survival than
tumor thickness in multivariate analysis. When excluding
Clark's level of invasion from the model, tumor thickness
gains independent prognostic impact.
Discussion
The importance of tumor necrosis and apoptotic activity
for melanoma development and progression has not been
well examined. In our study, necrosis was present in 29 %
of nodular melanomas and was strongly associated with
other features of aggressive tumors like ulceration, vascu-
lar invasion, and reduced patient survival as shown by
multivariate analyses. Increased apoptotic rate was also
associated with impaired prognosis. We here asked
whether the presence of tumor necrosis, as a morphologic
marker of tissue hypoxia [39], was associated with altera-
tions in cell adhesion molecules and more aggressive
melanoma features. As a novel finding, we found a strong
association between necrosis and increased expression of
the adhesion molecules αv and β3 integrins, suggesting a
relationship between tissue hypoxia and more invasive
melanomas. Experimental studies of melanoma cell lines
have previously shown increased expression of αvβ3
integrin after exposure to hypoxia [17]. Further, in studies
of melanoma xenografts, up-regulation of hypoxia-related
gene products has been associated with increased meta-
static capacity [40]. In our study, we found that necrosis
was associated with increased expression of both αv and
β3integrin subunits, thus validating the findings from cell
lines in human melanoma samples. It is hypothesized
that tumor hypoxia induces or selects for more aggressive
tumor features such as increased invasive properties and
metastatic capacity. Integrin subunits such as αv and β3
might play an important role in this phenotypic shift.
Both experimental [41] and clinical data [18,19,42] point
at β3 integrin as a marker of melanoma growth and pro-
gression, whereas the role of αv-integrin has been less
studied. Some reports indicate that αv  promotes
melanoma invasion [43], but others disagree [19,44]. Our
present findings indicate a significant impact of αv-
integrin on melanoma progress, as supported by associa-
tions with tumor thickness and presence of necrosis, and
we also show for the first time that αv expression is associ-
ated with reduced patient survival by multivariate analy-
sis. These findings might be of clinical importance, since
αv blocking agents with anti-tumor and anti-angiogenic
properties have been proposed as a treatment option for
melanoma patients [45,46].
Presence of necrosis was associated with altered expres-
sion of αvand β3 integrins which are considered important
for tumor cell invasion. We recently found that other cell
adhesion markers appear to be significant for the invasion
and prognosis of cutaneous melanoma, most notably a
Survival curves according to the Kaplan-Meier method by (A)  absence or presence of necrosis, (B) expression of integrin  αv, and (C) apoptotic index (AI) in nodular melanoma with  death of the disease as end-point Figure 2
Survival curves according to the Kaplan-Meier 
method by (A) absence or presence of necrosis, (B) 
expression of integrin αv, and (C) apoptotic index 
(AI) in nodular melanoma with death of the disease 
as end-point.
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shift towards expression of P-cadherin and loss of nuclear
β-catenin [2]. In the present study, both cytoplasmic P-
cadherin staining and loss of nuclear β-catenin were sig-
nificantly associated with tumor necrosis. Together these
findings suggest even further that tumor necrosis may
induce a shift in cell adhesion profile towards a more
invasive phenotype. Alternatively, hypoxia might induce a
selection of more aggressive tumor cell clones with differ-
ent molecular signatures.
Expression of selected hypoxia markers (HIF-1α, CAIX,
TNF-α, Apaf-1) was significantly stronger in melanomas
than in benign nevi, indicating possible roles in early
melanoma development. In our series of nodular melano-
mas, these markers also revealed some associations with
features of aggressive tumors like increased tumor thick-
ness and ulceration, and expression of two markers (TNF-
α, Apaf-1) were further increased in melanoma metas-
tases. However, cell adhesion markers (αv  and  β3
integrins) showed stronger associations with progression
markers and patient outcome.
Our study indicates that increased apoptotic index corre-
lates with melanoma development and poor patient out-
come in nodular melanoma. In line with this observation,
expression of Apaf-1, a marker of the mitochondrial apop-
totic pathway, was increased from melanocytic nevi to pri-
mary melanomas and even more so in melanoma
metastases. In contrast, previous studies have indicated
loss of Apaf-1 in melanoma cells when compared to nevi,
considered to represent an indication of reduced apop-
totic capacity in invasive melanoma [13,14,47]. Apaf-1
expression was also associated with increased tumor
thickness and strong staining of the pro-invasive αv-
integrin. Taken together, our findings suggest that higher
apoptotic activity is taking place in the more advanced
melanomas, but the proliferative capacity is increasing
even more, in favour of tumor growth and progression.
This is underlined by our finding of an association
between high proliferation ratio and increased tumor
thickness, indicating relatively higher proliferation rates
in tumors with abundance of apoptoses. Smaller studies
of apoptosis in melanocytic tumors and basal cell carcino-
mas have indicated similar findings [48,49]. Thus, novel
therapeutic approaches targeting cancer cells by inducing
up-regulation of apoptosis [50] could be attractive in
these tumors.
Recent gene array studies have identified osteopontin as
highly over-expressed in metastatic melanoma when com-
pared to benign nevi [28]. This is confirmed in our present
study of protein expression, where osteopontin staining
was increased from benign nevi to malignant melanomas.
Expression was even stronger in melanoma metastases
compared with corresponding primary tumors, in con-
trast to the study by Zhou et al., where no such correlation
was reported [28]. The level of osteopontin expression
was associated with both increased tumor cell prolifera-
tion and apoptotic rate, although not with patient out-
come, contrasting another recent study of melanomas
[29]. The mechanism of action is less clear, as there were
no significant associations with its receptors αvβ3integrin
and CD44.
Conclusion
Our findings indicate that hypoxia markers like tumor
necrosis and increased apoptosis are associated with the
progress of vertical growth phase melanoma of the nodu-
lar type. The prognostic significance of αv-integrin is
reported for the first time, and underscores the impor-
tance of cell-matrix interactions in melanoma invasion
and metastasis, supporting this as a potentially important
therapy target that should be further investigated.
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